163 results about "Liposome suspension" patented technology

A topotecan liposomal composition which can be reconstituted from a lyophilized form to an injectable liposome suspension having selected liposome sizes in the size range between 0.05 and 0.25 microns, and between about 85-100% liposome-entrapped topotecan is disclosed.

The invention provides a preparation method of a novel insoluble drug liposome without the application of an organic solvent in the preparation process. The invention names the method as a water soluble surfactant dispersion method. The preparation method comprises the following steps: A. an insoluble drug is dissolved or suspended or mixed in a water soluble surfactant; B. lipid substances, a water soluble diluent and the water soluble surfactant which is dissolved or suspended or mixed with the insoluble drug for forming the liposome are evenly mixed; C. the appropriate amount of water or water solution is added in the mixture which is obtained in step B, the even mixing is carried out, and the high pressure homogenization or the high pressure homogenization is carried out, thereby obtaining liposome suspension; D. other liposome components can be added by adopting the appropriate method in any step of the steps of A, B and C according to the physical and the chemical properties, if the insoluble drug liposome does not contain other liposome components, the liposome components can not be added.

Delivery of active ingredients by administration to an individual a vapor, aerosol, or liposomal suspension. Certain terpene solutions are employed for delivery.

A process for the large scale production of a liposome suspension, in which three selected lipid compounds in a predetermined ratio are dissolved in an alcohol solvent to form a mixture, which, in turn, is directly admixed with an aqueous ammonium sulfate solution in a predetermined ratio. The resultant mixture is subjected to a pore-extrusion treatment, followed by dialyzing the pore-extruded mixture with a 5% to 15% sucrose aqueous solution, such that a liposome suspension containing liposome particles suspended in the liposome suspension is obtained. The thus obtained liposome suspension can be used to encapsulate a selected drug, in particular doxorubicin.

A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension is administered over a period of time, whereby in the levels of some or all of blood glucose, insulin, total cholesterol, LDL cholesterol, triglyceride, creatine kinase (CK), creatine kinase-MB (CK-MB), Hb-A1_c, lipoprotein (a), SGOT and SGPT fall back within the normal range or are significantly reduced.

The invention discloses human umbilical cord MSC (mesenchymal stem cell) serum-free medium liposome freeze-dried powder, which consists of 1-3% of a human umbilical cord MSC serum-free medium active protein ingredient, 15-60% of phospholipid, 1-12% of cholesterol, 1-25% of Tween-80, 0.5-10% of a lipid-soluble antioxidant, 10-60% of a cryoprotectant and 1-5% of water. The invention also discloses a preparation method of the liposome freeze-dried powder, wherein the preparation method comprises the following steps: firstly, dissolving the phospholipid, the cholesterol, the Tween-80 and the lipid-soluble antioxidant in absolute ethyl alcohol, so that a raw material solution is obtained; then, adding the raw material solution to a buffer solution which contains the cryoprotectant and conducting hydrating; after conducting hydrating, removing all ethanol, and conducting ultrasonic granulation, so that a blank liposome suspension is obtained; and conducting an encapsulation reaction by adding a human umbilical cord MSC serum-free medium to the blank liposome suspension, conducting film filtration and granulation on a finished product, and sequentially implementing freeze-thawing and freeze-drying, so that the liposome freeze-dried powder is obtained. The liposome freeze-dried powder disclosed by the invention, which is directly added to cosmetics after being hydrated, has a function of delaying aging. The liposome freeze-dried powder disclosed by the invention is long in shelf life, good in cosmetic effect and free from immunological rejection.

The invention discloses a tramadol multivesicular liposome and a preparation method thereof. The preparation method comprises the following steps of: 1, dissolving phospholipids, cholesterol and neutral lipids into organic solvents to obtain a mixture which serves as an organic phase; 2, preparing 10 to 500mmol/L tramadol solution which serves as an internal water phase; 3, adding the internal water phase with the same volume as that of an organic phase into the organic phase, and mixing and emulsifying the mixture to obtain water-in-oil primary emulsion; 4, preparing an external water phase containing amino acid and osmotic modulators and/or surfactants, and adding the external water phase of which the volume is 2 to 10 times that of the water-in-oil primary emulsion into the water-in-oil primary emulsion, stirring the mixture to form oil-in-water type double emulsion; 5, adding the emulsion into the solution of the amino acid, introducing nitrogen or carbon dioxide into the mixed solution to remove the organic solvent from the emulsion to obtain suspension; 6, dissolving the suspension into the solution of amino acid, centrifuging and taking lower liposome suspension to obtain the tramadol multivesicular liposome. The prepared tramadol multivesicular liposome has the advantages of higher encapsulation efficiency, good slow release effect, and longer analgesic effect.

A method for preparing the liposome suspensions comprising liposomes with small particle size and uniform particle size distribution by performing an injection process in combination with a one-step extrusion, and further the liposome suspensions obtainable by this method as well as drug-encapsulating liposomes as well as a system for preparing the said liposome suspensions are disclosed.

The invention relates to a method for preparing gadol glycosides nanometer liposome suspension. Wherein, said suspension comprises the extractive of gadol as gadol glycosides and the nanometer liposome packing the gadol glycosides. The inventive production comprises that: dissolving the lecithin and cholesterol into absolute ether, depressurizing and vaporizing the organic solvent; adding gadol glycosides phosphate buffer with some surface activator, expanding, and dispersing at ultrasonic wave, to obtain the final suspension. The average grainness of product is lower than 100nm; the package rate of gadol glycosides can reach 25-35%.

The invention discloses a preparation method of radix rehmanniae polysaccharide liposome, which comprises the following steps: taking soybean lecithin, cholesterol and Tween 80, dissolving in a solvent, and carrying out ultrasonic dissolution; carrying out vacuum evaporation at 30-70 DEG C to remove the organic solvent, and adding aether for dissolution; introducing a radix rehmanniae polysaccharide PBS (phosphate buffer solution) into a reaction vessel to form a two-phase system, and carrying out ultrasonic treatment in an ice water bath to form a stable W/O emulsion; carrying out vacuum evaporation at 30-70 DEG C to form a colloid, adding the PBS, and continuing rotary evaporation to remove the organic solvent; carrying out ultrasonic treatment in an ultrasonic cell disruptor until the radix rehmanniae polysaccharide is fused in liposome, thereby obtaining a radix rehmanniae polysaccharide liposome suspension; and extruding the suspension respectively through microporous filter membranes to obtain the radix rehmanniae polysaccharide liposome. The radix rehmanniae polysaccharide is prepared into the liposome for the first time, and the preparation method of the radix rehmanniae polysaccharide liposome is a reversed-phase evaporation process; by optimizing the response surface, the method can maximally save the raw material and obtain higher drug entrapment efficiency; and by combining the ultrasonic action, the prepared liposome has higher uniformity and higher stability.

The invention discloses a probiotics liposome and a preparation method thereof. The particle size of the probiotics liposome is (143.87+/-10.58)-(161.53+/-11.62)nm, and the encapsulation rate of probiotics in the probiotics liposome is 40-57.14%. The method includes steps: (1) preparing a lipid film; (2) preparing phosphate buffer solution; (3) dissolving probiotics into the phosphate buffer solution to form mixed solution 2, and preheating; (4) forming liposome suspension; (5) subjecting the liposome suspension to ultrasonic treatment, filtration and hydration to obtain the probiotics liposome. The probiotics liposome is prepared aiming at the problem of proneness to inactivation of probiotics in a digestion process of the human body, stability and activity of encapsulated probiotics in the human body are improved, the survival rate and setting quantity of probiotics in the intestinal tract are increased, and accordingly probiotic effects of probiotics can be truly achieved.

The invention relates to a recombinant human epidermal growth factor cationic liposome and a preparation method thereof. The recombinant human epidermal growth factor cationic liposome comprises a recombinant human epidermal growth factor, a cationic liposome and a growth factor protective agent, wherein a part of the recombinant human epidermal growth factor is encapsulated by the cationic liposome. The preparation method comprises the following steps of: step 1. dissolving a panniculus adiposus material and a cationic additive by an absolute ethyl alcohol, carrying out rotary evaporation to get rid of the alcohol to form uniform panniculus adiposus, and adding a citrate buffer solution and hydrating to obtain a crude liposome suspension liquid; step 2. carrying out ultrasonic dispersion to process the crude liposome suspension liquid, and straightening particles by microfiltration membranes to obtain the blank liposome; and step 3. adding the blank liposome solution after mixing a recombinant human epidermal growth factor solution with a growth factor protective agent solution, adjusting pH to 6.0-8.0, and carrying out incubation processing to obtain the recombinant human epidermal growth factor cationic liposome. According to the preparation method, the human epidermal growth factor can be encapsulated by the cationic liposome so that the stability of rhEGF, the intermiscibility of tissues and the affinity of cells can be increased.

The invention discloses a strychnine compound phospholipid liposome which is prepared by two types of phospholipids, strychnine and cholesterol in certain weight ratio. The preparation method for the strychnine compound phospholipid liposome comprises the following steps: (1) dissolving the first type phospholipid, the second class phospholipid and the cholesterol in absolute ethyl alcohol, and injecting the aqueous solution of ammonia sulfate into the mixture ; (2) removing the alcohol through heating or decompression method; (3) carrying out ultrasonic processing or high-pressure emulsion homogenization to reduce the grain size of the liposome; (4) removing the ammonia sulphate which is not encapsulated by the liposome through a dialysis method, an ultrafiltration method or a gel column chromatographic method so as to form blank liposome suspension; and (5) adding the strychnine into the suspension, and carrying out moderate incubation so as to enable the strychnine to be encapsulated by the liposome. The strychnine compound phospholipid liposome has significant characteristics of high encapsulating rate of the liposome for the strychnine, greatly improved stability, no easy leakage, and remarkably improved medicine carrying capacity. The results of tumor resisting experiments show that the cancer resisting effect of the strychnine compound phospholipid liposome is remarkably higher than that of a common single phospholipid liposome.

The invention relates to glabridin freeze-dried liposome and a preparation method thereof. The glabridin freeze-dried liposome comprises, by weight, 65-70 parts of soybean phospholipid, 30-35 parts of cholesterol, 0.5-3.0 parts of glabridin, 1000-1500 parts of anhydrous ethanol and 70-120 parts of a phosphate buffer. The preparation method comprises the following steps of 1, weighing soybean phospholipid and cholesterol, putting the soybean phospholipid and cholesterol in an eggplant-shaped bottle, and dissolving the soybean phospholipid and cholesterol in anhydrous ethanol, 2, carrying out decompression on the eggplant-shaped bottle to evaporate the solvent, 3, preparing a glabridin solution, 4, preparing a glabridin phosphate solution, 5, preparing a glabridin freeze-dried liposome suspension, 6, preparing glabridin freeze-dried liposome by a freeze-drying method, and 7, carrying out vacuum-pumping by a freeze-drier for 5-10min so that water is completely evaporated and the glabridin freeze-dried liposome is obtained. The glabridin freeze-dried liposome has a reasonable design, has very strong external transdermal absorption performances and provides experiment basis for a bio-pharmaceutical industry.

The invention relates to a method for preparing nicotinamide-coated multivesicular liposomes. The nicotinamide-coated multivesicular liposomes are prepared from phospholipid, neutral lipid, cholesterol, an organic solvent, a hydrophilic emulsifier, nicotinamide, amino acid, an osmotic pressure regulator and deionized water. The method comprises the steps: dissolving the phospholipid, the cholesterol and the neutral lipid in the organic solvent, so as to obtain an organic phase; uniformly mixing the nicotinamide, the amino acid, the osmotic pressure regulator and the deionized water, so as to obtain an internal water phase; homogenizing the organic phase component, and adding the internal water phase component into the organic phase component, so as to prepare a W/O primary emulsion; mixing the hydrophilic emulsifier, the amino acid, the osmotic pressure regulator and the deionized water, and carrying out dispersing, so as to obtain an external water phase; homogenizing the external water phase component, adding the W/O primary emulsion component into the external water phase component, carrying out homogenizing, then, carrying out ultrasonic treatment, and then, cooling the mixture to room temperature with stirring, so as to form a W/O/W multiple emulsion; dispersing the multiple emulsion into an amino acid solution, introducing nitrogen gas into the solution to remove the organic solvent, thereby obtaining a nicotinamide-coated multivesicular liposome suspension. According to the method, the stability of the nicotinamide is improved.

The invention relates to a preparation method of a cyclodextrin inclusion compound liposome with a whitening effect. The method comprises the following steps: A, weighing extract of haematococcus pluvialis and extract of laminaria ochroleuca to prepare an ethanol solution; B, weighing hydroxypropyl-beta-cyclodextrin to prepare an aqueous solution of cyclodextrin; C, uniformly mixing the ethanol solution and the aqueous solution of cyclodextrin, centrifuging to filter out precipitates and carrying out liquid drying to obtain a cyclodextrin inclusion compound; D, weighing hydrogenated polydecene, hydrogenated lecithin and sucrose dilaurate, mixing and heating to obtain a liquid oil phase; E, weighing the cyclodextrin inclusion compound, palmaria palmata extract, pancratium zeylanicum extract, daisy extract and deionized water, mixing and heating to obtain a liquid water phase; F, adding the liquid oil phase into the liquid water phase to carry out homogenizing so as to obtain liposome suspension; G, freezing and drying to obtain the cyclodextrin inclusion compound liposome with the whitening effect. According to the preparation method, various active matters can be simultaneously loaded; the technical defect of poor compatibility between various active matters is overcome; percutaneous permeability and slow-release property of the active matters are improved.